STEPHENS ANNUAL INVESTMENT CONFERENCE | NASH2026 - CASTLE BIOSCIENCES INC
All right. Well, welcome everyone to day two of the Stevens Conference. I'm Mason Carrico. I'm the Diagnostics and MedTech Analyst here. Happy to have Castle Biosciences joining us here today. We have Derek Matzold, CEO. Appreciate you coming, Derek. You're welcome. Good to be here. Maybe the first place or where we can start here is just Q3. You guys just reported. Maybe just give us a quick overview of the quarter. What you would point to is kind of the key highlights and main takeaways you want investors to have coming out of the print? Sure. So we, I think, performed as we expected in the third quarter this year. We had 24% revenue growth year over year. That's after seeing our SEC revenue wind down with the Medicare decision in April 2025. So, we're heading into 2017 in a strong position. We increased our guidance, I guess midpoint up by $20 million. So I think we'll close in between 385 395 million. This year, we end up with 12.7 million in adjusted EBITDA, I think 19.7 money in free cash operating flash flow, I thinking then added to our balance sheet. So we're sitting at about 278 just shy of that million in cash and cash equivalents and marketable securities. So it feels like we've done what we believe we would do a couple of years ago, which is to build a strong balance sheet and came to be growth-based blocker diagnosis company that's profitable and tissue cipher asp has been strong throughout this year i guess what's been the key tailwind that's driven that throughout 2026 i think we've seen continued success in appealing and getting paid properly by commercial payers is probably the most significant part there a couple of commercial payer wins here and there but the evidence of the utility of the test is strong It's hard to justify not making an appropriate payment, I guess I would say. Secondarily, we also made some adjustments to our accrual of tissue cipher commercial revenue in 2027. So there was some overlap between cash collection accounting versus accrued accounting in part of the year. So that provides a little bit of a uplift overall, which hopefully will wind down by the time we get X at 26. And so 27 is a little cleaner, but ASPs did improve, yes. And I think you guys have kind of mentioned that you don't assume incremental upside to ASP from here, but maybe whether it's tissue cipher, I guess, decision DX, melanoma, if we were to see improvements in 2027, where would they come from? Is it, you know, incremental commercial wins? Is it appeals? Is it Medicare Advantage playing better? What do you, I guess, see as an opportunity? As buckets there. So straight Medicare claims are pretty easy to forecast and manage. We don't submit claims that don't fit the policies we've agreed to. So that's a, you Know, 100% payment rate unless you have something goofy. um medicare advantage um claims um should be of course paying along with medicare um the industry has some issues with prior authorization some other um um behaviors i guess that tend to to reduce that a bit we've seen improved success over the course of the year and are approaching and dealings with medicore advantage plans and payers to say hey hey, this is the way it should be and should be is. So that's improved in terms of the percent of payment we get of 100 claims going out. Commercial payers are picking up as well. I don't know how much of that could be kind of a buyer market-driven activity or how much is not or just generalized good technology overall among both those tests there. And then I guess sticking with Q3 and tissue cipher here, You called out, I think, on the call that volumes for tissue cipher were mainly driven by higher utilization among existing users and that new ordering clinicians contributed less so. How is the pace of new clinician ads kind of tracked throughout 2026 compared to maybe what we saw last year? Yes, we give out annual numbers only on that. My census will be closed out 2026. we will see very healthy growth in first-time ordering clinicians, and we will See an increase in going deeper in, I guess, clinicians who are ordering prior to 2026. There are still, it's interesting, of course, they even look at melanoma and say you've been out with melanoma for 12 years or so. You still find clinicians who have dermatologists who have a low level of knowledge on some of those are fresh out of residency programs where you aren't able to impact them in terms of educate them on the test some of those are older clinicians or or difficult to see so even after years of trying to get them around it's like well i had no idea this is how it's used um we're obviously much more younger and in the gastroenterology team having acquired synostics only in late 2021 um so there are still plenty of clinicians who have minimal to no knowledge of tissue cipher which is just amazing in this day and age of information sharing. Um, so those are going to represent an important component of growth going forward. We also see in sort of, if you want to view same store sales, it's difficult to understand how a gastroenterologist would sort of segment the marketplace of his patients or her patients. Um, if a patient has Barrett's esophagus disease and it's non-dysplastic, which is about what, 94, 95% of all patients diagnosed, um, some of them might have other risk factors that could be older they could be male could be smokers could be obese but everybody's at risk of progression and so how do you as a clinician decide which patient I want to order a test on which patient I don't that's very difficult in Barrett's disease and so we typically see they'll kick the tires initially because that's what we should all do I guess you would say before you buy the whole car but I think once they're on board it's a matter of saying how do we kind of get the workflow to work so that you aren't missing the ones you intend to go and order the test on and That's different than skin cancer where you've got patients with really, really thin melanomas where a dermatologist may say, I've never seen one metastasized. So even though I could order your test, I think it's just going to reaffirm a low risk result. That doesn't really exist quite that way in Barrett's esophagosies with the GI team. Yep. And I think even at a recent conference, you guys may have talked about how once a GI adopts tissue cipher they they do usually use it across um all of their barrett's patients at least that are you know applicable to tissue ciphers and you flagged you know staff turnover um kind of the office workflow is maybe kind of the gaps there i guess what are you doing to close those gaps what's commercial strategy there how much headroom do you think you still have left within your current ordering base yeah so i think um um we are making headways that we hope are sticky So part of the structural issue that exists in gastroenterology that we do not see in dermatology, just to give a comparison within CASEL, is in dermatologie, it's the dermatologist or the MP or PA in that practice location with their office staff, MA, LPN, nurse, whatever their support staff is. They're doing a, this looks like a mole, we're going to biopsy this, mace, and if it comes back, melanoma, I'd like you to make sure I order the CASEL test for that patient. Easy flow, same patient, same continuity. In gastroenterology, you have a gastroenerologist who sees patients in his or her clinic location with his or his clinic staff. And then separately, sometimes miles away, is the ambulatory care center with a surgical staff support who does not go back to the clinical staff. And so if you're in the ambulator care center or the endoscopy suite and you're doing an upper GI and you see the salmon color esophagus and you say, yep, this looks like it's Barrett's let's do a pinch biopsy or let's do a Seattle protocol do multiple biopsies you turn to your surgical nurse or support staff and say hey this comes back Barrett so let's make sure we order the castle test the problem is that that person never sees the diagnosis because pathology goes to the EMR system in the clinic and that surgical staff doesn't work in the clinical staff and so you've just got this breakage of a system so one area is how can we get that workflow that surgical stuff is talking to the clinical stuff routinely about what i guess our test there's no motivation for that that's a breakage there the other thing is what can you automate so that within the emr system when they file when they report comes back in with a with one of the ic10 codes of barrett's disease that gets flagged by the ma or the lpn to put in front of their clinician and say do you want to order the test those are good um some electronic solutions some just hand holding um at least your turnover though is that is that if you see these an ma um you know leave or be reassigned to different gastroenterologists the new one comes in they're trained to go ahead and take dictation take notes know the workflow without necessarily training our test so that's kind of the breaks that we need to work on the workflow and we're seeing some improvements as groups put in more practice wise uh protocols like you might see with colonoscopy referrals etc right and maybe on that topic to some degree uh maybe it was the beginning of the year you guys talked about larger gi practices maybe pi pe back practices adopting these formal protocols and i think at that time you guys said you know it wouldn't really show up in volumes this year maybe you guys are early on that initiatives but um it does seem like some practices at least are starting um to make tissue cipher standard on a small scale how many groups have a formal protocol or standing order in place i guess Where are you on that issue? So we're further along now than we were last year. I know that sounds very, very avoiding your answer. I don't have a quantitative number for you. I would say that we've been pleased to see the number of practices, be it, you know, one location with 20 gastroenterologists or a small group practice, a small PE grad practice, who said, hey, we've had enough experience now in two or three or four years a tissue cipher that I'm wondering why we are letting a referral in going to you as a GI or me as aGI and the patient gets different care levels because you don't use tissue ciphers, I use tissue cypher. And so there is no profit motive to have them order our test, really. It's not like we're selling cheaper devices or cheaper endoscopy scopes. So none of that from a sort of financial recommendation comes out. us really saying, good medical care is this a plan that we as a group of clinicians want to implement? If so, let's do it and figure out how to get into the EMR workflow or somewhere so back so it happened. So we are seeing gains there. I think we saw I don't think we cover this earnings call like we did. The, the American Forgot society. He should get their practice update guidelines and with concomitant with their with our October meeting this year that placed tissue cipher in a nice recommendation spot as we see it that hopefully helps more groups accelerate a more you know clinical care pathway for bariatric esophagus management as opposed to just a a individual clinician basis in using like the 20 gi practice kind of example if you have five six whatever it is gi is using tissue cipher and a formalized protocol gets put in place how quickly do you see the rest of the, uh, the rest of the GIs at that practice adopt? Um, that's probably too much detail to give you a fair answer. I, um, I think that I think of a couple of examples that I've been aware of. Um, there's one practice in Texas where the, the interventional gastroenterologist or upper endoscopy guy. So the individual who actually does the ablations or leaves the, the esophageal eradication uh therapy or surgery procedure um um i'm using it um patients referred to me i'd like you to use it on patients you refer to me so we get the patients who i can intervene with we can stop cancer um that probably takes less than a majority to say hey i'm the one i'm your interventionist who's who's treating these people i trust this test to find high risk on biology i trust our pathologists to find high risk on pathology i want to treat high risk people get this test ordered in practice so we've seen that kind of of where it's the interventionists pushing down so this is good care um and that's easier than sort of a if they're if you have a practice of just regular gastroenterologists where nobody's doing ablative therapy that's outsourced to a different location that's probably more of a majority owns as opposed to a single leader or a minority leadership goes got it um from a sales force perspective i think the gi team is now around 100 reps or so how many do you think we're operating it at full productivity in q3 um and i guess when you think the last cohort higher i guess whenever that was when do you say when do you essentially think all 100 will be productive so we um had our last reasonable expansion of a couple regions here and I want to say the May June time period so third quarter still reasonable training criteria I would say I will see more productivity I would think this year but I would probably say in terms of being a fully effective we still model training about six months to get not only product trained but also go through a couple of cycles if they have not been in that same gastroenterology territory learn learn the the office dynamics on a surgical suite dynamic so we can have the maximum impact so we we should be seeing uh so so third quarter i've already had some versus none we should see more in the fourth quarter and maybe that helps us as a different jumping spot offer for 1q 2027 going forward okay um and maybe before i ask about your non-endoscopic collection device i want to ask i think lucid's getting paid now on a claim by point claim basis that's what i saw yeah yeah um how much of an impact do you think that could have as a feeder for new tissue cipher patients yeah so it's interesting so they've um certainly seen volumes change quarter to quarter um i think that now with the um with the claim by claim payment for their test out of out of um novitas the jurisdiction texas one that's probably just an evil part of where it should be anyways and hopefully moldy X finalizes their, their, um, reconsideration on the original LCD from a couple of years ago, it was quickly, um. Um, and that provides a second sort of positive outcome there. So assuming volume picks up, there are a couple other players in that area that might, you know, begin to commercialize different kinds of balloons or sponges. Um, um and, and to me, if, if those are, are successful in finding people who have symptoms or signs that are high enough risk to get scoped quickly, then that should increase the funnel, you would think, just naturally speaking versus a normal flow of a patient eventually getting referred into a GI. So I don't know how much impact that would have sort of in the first half of 27. I think that if those companies staff up in terms of their sales teams, volume drives, maybe that's the late 27, but certainly you would thing 28, 29, 30, acceleration of kind of baseline number of patients diagnosed each year. Okay. Where does your device stand from a development standpoint? How should we think about, I guess, the timeline to launch and ultimately, I Guess also the payment path or strategy there? Is it more about driving, you know, patients to tissue cipher, and you get paid there? How do you, I um, a tether sponge technology and some, um, IP out of, uh, with the XNIP revised back in this, I guess, summer 25, right? So a year or so ago, um. One of our criteria for moving that forward quickly was seeing outcome of something like this. I was expecting to see multi X outcome as opposed to Novotos claim by claim, but that's a good, a good thing. Uh, we are in development with that at this point in time for a number of, of, or we are in development we'll be developing for a number of interesting GI diseases Barrett's being probably the leading one because of a payment path here um uh so we'll probably update after the first year I think what are what some milestones would be in terms of timelines for for clinical data development data and potential launch ranges I would hope for that they're supposed to doing it here regarding um um uh the second half of your question got to restate that slowly payment payment pathway so So, so an important element for us is assuming the mix for, for patients who'd be, who'd be taking a, a, swallable product that you then pull back out is close to the same as tissue cipher. I don't think why it would be much younger necessarily when a mature marketplace, then you're probably talking 50% of people who are over 65 years of age and 50% obviously below. close to tissue cipher that holds up then you've got half the marketplace priced and supposedly in a in a payment preparation that's not that's a very nice place to launch into by the way um i think commercial payers um will have to see how if that market matures quickly or slowly um what's the benefit of finding a patient with bearish disease from an insurance carrier standpoint they require a an inordinate amount of evidence from lucid or others to kind of get there or will they say, actually, this is a pretty good thing for human health? It's part of what we can do. Price point's not that great. If we can go ahead and stop a patient from progressing to esophageal cancer when they're in our same health insurance system, that's huge dollars of savings based upon the morbidity and the expense of treating that disease. Maybe moving to melanoma, the guide was narrowed to mid-single digits. I think it was mid-to-high from a volume perspective. Is mid-single-digit volume growth the right way to think about melanoma volumes going forward? I think so. It's interesting how promotionally responsive, after this many years in the marketplace, these tests remain to be, or at least melanoma is. So we certainly, as we talked about, I think on third quarter earnings, to refocus our sales force in the middle of third quarter because we see promotional responsiveness in the past. I think right now we're going to come out probably, if you use $130,000 as your base versus $100,000 incidents per year of invasive melanomas, we're testing one in three or we're investing in four in ten patients today, at least that penetration here. we believe that the utility of this test as it currently stands i think gets to 60 penetration so i think mid-single digits is what i think is a is a safe road um to go ahead and play for right now what changes that um uh do we see after success of maybe uh a vaccine immunotherapy approach going from later stage melanoma upstream to stage 2a or 1b if we could have an intervention like that impact melanoma outcomes, I think then you would say this feels like breast cancer interventions. This feels like tissue cipher interventions where you actually change with a test result and outcome in near term. I think that's where it might go from 60% to 80% or higher in terms of total marker penetration over time. Absence of that, then 60% penetration probably is about the right thing to think about modeling. Got it. Okay. um and i think the nccn panel may have met for melanoma may have met in late july sometime in the summer maybe should have um did did you submit any additional studies for this review that maybe weren't part of the last review um and I guess how are you kind of thinking about the opportunity for decision dx to be incorporated into the 2027 version to some degree so um um we did submit new published data that had come out since i guess july of 2025 um certainly um our belief is that our our tests as to the the face of time i think over now 58 publications showing consistency of results of risk of recurrence we're testing one and three one and four and ten patients today um we're seeing that that when our tests are studied either prospective retrospectively, the test actually works in terms of what it should do. That should mean it should be used, it should be incorporated clinically in as appropriate manner. So my, my expectation is that if the data is read in a logical fashion, and this should be inserted in a positive manner coming January 2027. If not, that's the way it's been for several years. We haven't really talked about this back post COVID or during COVID, there's actually an insertion about using our test to go make the same decisions the next year the panel change all of a sudden the evidence wasn't deemed to be well enough so they pull that back so we have seen ebbs and tides of this and hopefully this is an opportunity gotcha um and maybe on adtx um cms proposed a gap fill instead of using the panel's unanimous recommendation to crosswalk um i think on the q3 call you may have said you submitted an alternative crosswalk to that have you talked about what comparator you proposed um and kind of the response there the rate and is there a precedent of of cms reversing i guess a preliminary gap fill in the final recommendation okay there's a lot of questions sorry i'm gonna unwind that stuff so um so um we had identified a a a test that was priced on the cfs schedule back in the springtime submitted that for recommendation because it seemed to be the closest to us it was a next gen sequencing run gene expression profile test and RNA was used in that that test was used in psoriasis to help predict responsiveness to classes of drugs. Our test is using atopic dermatitis using NGS backbone for RNA purposes in atopic Dermatitis to predict response to class the drug it seems like a like a pretty easy thing which the advisory committee to cms also thought unanimously and then you know a week or two later cms says well gee by the way they didn't submit any to pamma data so therefore we're not going to let you price against a rate we said not the marketplace so i said okay that's would have been nice to have information like three weeks beforehand so we could have changed a few things by theway and met your needs but that's that's how timing goes um and that led to the preliminary gap field which was pretty clear saying we can't find the ngas based rna test that that we can crosswalk to. Therefore, our choice is to go back on the contractor's price or the course 27. We submitted where we requested and had a call with the team as a CLS group in October prior to submission and walked them through what we'd seen and found. This is their decision, not mine, but I would say they were unaware of at least the two tests we felt were most similar, which are multi-analyte RNA-based tests using NGS technology that were priced using private payer data. And that we weren't aware of those that seems appropriate. If they end up reviewing the data that we submitted them in a, I would call it fair and open conversation, I would just say it's pretty clear that if there's an appropriate crosswalk test, that should be that the mandate is a crosswalk, not the gap fill. So we'll know here in two or three weeks of that was taken as the action step. I think they usually will post an early to mid December, the rates for January 27. If they select one of the two of the tests that we felt were most easily aligned to that based upon work product and work code underlying platform, then that's in that same $1,300 range plus the last couple of dollars. So I think that's we feel like we're in the same place there. If the end up saying no, we recommend gap feel we can't, you know, have a have a Hail Mary touchdown at the other day, then I think it behooves us a castle to just disclose when we receive Medicare payments saying we've been contractor rated and here's our price for 2027 by this contractor. So that just creates a slight cloud in terms of what that rate would look like. To me, crosswalk is a natural outcome we should get to. That lets us begin different conversations with commercial payers because now there's a public Medicare rate they can tag to. We can discuss as opposed to more of an arbitrary conversation. And that just is one more notch going forward in terms of beginning to drive AD volume going up. Okay. And I think you've talked about intentionally kind of gating volume until you have more visibility around ASPs and reimbursement. Would getting the crosswalk trigger the next tranche of expanding access for that test? That's one of the triggers there. I think we take a step back in. If our numbers are close to correct, we have, what, 8 to 10, 9 to 11 million patients in the U.S. who are above 12 years of age, older, who have moderate to severe atopic dermatitis that our tests could be used on. You know, aspirational TAM maybe, but as called, that's what it is. So if that marketplace is close to realistic, you're talking about, what? 20-fold the size of tissue cipher. This this this advanced A.D. test, especially given the early clinical utility outcomes that we're seeing coming from independent clinicians using our test lines up with our with our prospective validation study. We need to begin generating appropriate volume in twenty twenty seven, I think, on a measured basis so we can meet our revenue goals, our profitability guidance goals so that, you know, perhaps as early as twenty eight. But hopefully in 29, 2030, this becomes the revenue contributor that we expect it to be going forward. So I think 27 represents a nice opportunity of having some of these milestones like a published rate that we can hold commercial payers to. Perhaps we go and start gaining some Medicare coverage, even though that's a small part of the category, maybe 20 percent or so. But that all triggers up to saying now we need to begin growing volume on a measured basis so we can make sure that we're hitting our sort of internal 29, 20, 30 contribution margins. Got it. Okay. And maybe pivoting to SEC on the Q3 call, you guys talked about maybe a draft potentially in the next quarter or two, maybe that not being an unreasonable expectation with or without a CAC meeting. I don't think we've heard from you before, like calling out, I guess, the CAC meetings and things like that. So I guess has something changed in terms of your engagement with novatas or palmetto that's maybe made you more optimistic about regaining that especially and and maybe to be more specific talking about sec being in your 2028 plan which it may have always been um but maybe we just don't know if i was too pessimistic before i got to pull that one back i guess that was a mistake um i think um there's a to break some of those um comments apart I look to the CAC meeting that Moldy excelled, what, September of last year for the Lucid product. That hasn't finalized out. I don't know how much of having Dr. B.N. Willner depart in second quarter caused delays in finalization. You would think that should come soon, I would guess. You look at the CACH meeting that Novotov scheduled for the bladder cancer test, I guess it was. in I want to say April time period I think it was draft LC came out a little bit later and then you had a finalized either earlier this month or late November so the use of a CAC meeting by Novotov seems at least for an N of one a hundred percent so maybe that's a drive towards that so I don't mean to mislead that that's the way to go or not go but that's part of the regulation process they can't come to a conclusion internally is to seek help from experts there so i didn't mean to have it be a change in in timing i think from a a expectation in 27 i guess the one thing which is nice is that we're not sitting here and in december 2022 with novitas coverage which we had back then with the sec test but a much different company really still a a you could almost call it two product company right melanoma and squamous cell carcinoma tissue cipher was just getting going you advanced forward a couple of years here and all of a sudden we were a different revenue company a different profitability company healthier balance sheet regaining squamous cell coach the moment is important to me because it's important from a patient care standpoint and when it comes online it all drops down to the bottom line which is fantastic on the other hand if it never comes through we built a great business in the interim three years with advanced ad coming through here now we have a plan to grow and meet our revenue goals and our building goals pretty comfortably i guess i would say sec is a is a important element i would Say it's nice to have now versus i would not necessarily need to have but it makes sense to you so why 28 i think um i think if we see daylight from novatas the next quarter or two either a cac meeting or draft do we count on their urinary bladder six month timeline as being what they're going to do it's only n of one so it's hard to hard to between that but it could be that early so that could be later in 27 right i think 28 is a little more conservative to say hey let's not get anxious about this being some kind of a watershed event for castle um it ends up being moldy x uh post the draft lcd first i'm unaware of when they have not taken the full year from draft to finalization yeah now that was with the old guard in town there's a new guard here now I mean, maybe things will change, but there's no roadmap to say that's going to be the case. So that was the only rationale to make those kind of comments. Got it. Okay. And then I guess as we kind of wrap up here, you guys expect positive adjusted EBITDA in Q4 next year as well. I think maybe your margin in Q3 was something like 12.5%. How do we think about the margin trajectory here? Sales teams have scaled. I know that there are some pipeline investments, but how should we think about, I guess, the margin profile or expansion opportunity? Yeah, so maybe I'll stop at – I'll start at gross first. Adjusted gross, we came in very strong for 77%, which is what we had a year ago. That's kudos to the efficiency of the lab. I think as we go into 2027, as we scale, I guest you would say, the advanced AD test results, there could be some pressure on a couple of points perhaps i think we've always said 70 75 is about where we should be at which is a great place to be still relatively market leading for our diagnostic space in terms of adjusted gross margin um the only thing that would pressure on that you know going from 77 south a couple points is going to be 80 volume growing i guess you would say in advance of reasonable reimbursement um tissue cipher is um the the spatialomics platform arm is not as efficient as seeing expression profiling. So that's some pressure there but I think I think in that in that being a mid 70s is probably right it gets to low 70s if volume goes up on ad quickly. So, that's and then drop that down the next leveraging arm. So I think the rest of the, of the of the the operating expense lines. We, we should be investing in some tissue cipher GI expansion just based upon the opportunity and seeing territories get too many current users so you either spend all your time servicing existing accounts and no time how many new doctors are going to balance it out so we will undoubtedly have measured expansions in that fashion which would just make sense business-wise right thankfully with the reimbursement profile of that test and the volume those become cash flow positive when what six eight weeks of being hired so that's not a something we'll be concerned about from a profitability metric won't let us grow as fast, but it gets leverage quicker. Dermatology side, same kind of opportunity there, I think the melanoma test alone plus a residual squamous cell payments and ad, let us go ahead and scale that as needed on sort of expansion basis, we can handle both the promotion responsiveness for melanoma, as well as getting going going up in a careful manner. So we would expect some of those to go forward in 2027. We should therefore be seeing operating leverage at least on the SG&A line. I mentioned R&D investment. So we have the this CCD product you mentioned earlier, there were a couple of milestones we'll look at there that might say, hey, we see such great opportunity, we're going to pull forward some studies, some investments, but that's for the good, won't push as a negative adjusted EBITDA might just say, Hey, I need to take some my room here and put it back into investing. And then on the other collaboration we have externally with Sybase in Sweden, is they have this electrical impedance spectroscopy technology, which is essentially a highlighter pen, with a lot of tricks and whistles to an app on your phone. And if the early reads on that study are productive, then I would expect us to push more dollars into R&D for that product and get it ready for launch, just for the first indication, but also second indications. That has the opportunity to be the single biggest product council ahead of ad if in fact, the results materialize as we expect. So I think we have some great upsides that could drive significant revenue along the ladder of our 2020 and 30 and beyond and just late stage pipeline opportunities that we should make the right R&D call if we need to, recognizing way advanced leads from a knowledge base from our investors and for you, as well as making sure that we're still in a profitability mode of position we want to be at. Got it. All right. We can stop there unless there's anything, any other questions from anyone here. All right, well, thank you, Derek. Yep.
- Company
- CASTLE BIOSCIENCES INC
- Keywords
- CASTLE BIOSCIENCES INC